Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LXRX
- CUSIP: 52887210
- Web: www.lexpharma.com
- Market Cap: $1.7869 billion
- Outstanding Shares: 105,235,000
- 50 Day Moving Avg: $15.49
- 200 Day Moving Avg: $15.08
- 52 Week Range: $13.01 - $19.62
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.77
- P/E Growth: -0.21
- Annual Revenue: $89.14 million
- Price / Sales: 19.80
- Book Value: $1.28 per share
- Price / Book: 13.10
- EBIDTA: ($143,170,000.00)
- Net Margins: -158.68%
- Return on Equity: -81.46%
- Return on Assets: -29.06%
- Debt-to-Equity Ratio: 0.63%
- Current Ratio: 2.04%
- Quick Ratio: 2.03%
- Average Volume: 859,500 shs.
- Beta: 0.51
- Short Ratio: 22.53
Frequently Asked Questions for Lexicon Pharmaceuticals (NASDAQ:LXRX)
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, August, 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.03. The company earned $20.10 million during the quarter, compared to analysts' expectations of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 81.46% and a negative net margin of 158.68%. Lexicon Pharmaceuticals's revenue for the quarter was up 5186.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
When will Lexicon Pharmaceuticals make its next earnings announcement?
Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?
6 analysts have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their predictions range from $21.00 to $38.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $28.00 in the next year. View Analyst Ratings for Lexicon Pharmaceuticals.
What are analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
- 2. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)
- 3. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/17/2017)
Are investors shorting Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 15,995,895 shares, an increase of 8.0% from the May 15th total of 14,806,106 shares. Based on an average daily volume of 850,640 shares, the days-to-cover ratio is presently 18.8 days.
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Juno Therapeutics (JUNO), Intercept Pharmaceuticals (ICPT), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC (GWPH), Axovant Sciences (AXON), AveXis (AVXS), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Halozyme Therapeutics (HALO), Radius Health (RDUS), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Sarepta Therapeutics (SRPT), NovoCure Limited (NVCR), Array BioPharma (ARRY) and BeiGene (BGNE).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Raymond Debbane, Independent Chairman of the Board
- Lonnel Coats, President, Chief Executive Officer, Director
- Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
- Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer
- Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations
- Alexander A. Santini, Executive Vice President, Chief Commercial Officer
- Praveen Tyle Ph.D., Executive Vice President - Research and Development
- James F. Tessmer, Vice President - Finance & Accounting
- Philippe J. Amouyal, Independent Director
- Samuel L. Barker Ph.D., Independent Director
Who owns Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (4.00%), Eagle Asset Management Inc. (2.73%), NEA Management Company LLC (2.28%), Kingdon Capital Management L.L.C. (1.61%) and State Street Corp (1.56%). View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., TIAA CREF Investment Management LLC, Goldman Sachs Group Inc., Columbus Circle Investors, Moody Aldrich Partners LLC, Teachers Advisors LLC, SG Americas Securities LLC and KCG Holdings Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Highbridge Capital Management LLC, Point72 Asset Management L.P., Sector Gamma AS, Renaissance Technologies LLC, Kingdon Capital Management L.L.C., Bank of America Corp DE and Old Mutual Global Investors UK Ltd.. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy Lexicon Pharmaceuticals stock?
Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $16.77.
Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 5 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.83)|
|Consensus Price Target: ||$28.00 (66.96% upside)|
Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
(Data available from 6/29/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/3/2017||HC Wainwright||Set Price Target||Buy||$27.00||High|
|4/5/2017||Needham & Company LLC||Reiterated Rating||Buy||$21.00||Medium|
|3/7/2017||Citigroup Inc.||Boost Price Target||Buy||$24.00 -> $28.00||N/A|
|3/1/2017||Wedbush||Boost Price Target||Outperform -> Outperform||$33.00 -> $38.00||N/A|
|12/23/2016||Cowen and Company||Reiterated Rating||Market Perform||N/A|
|8/5/2016||Stifel Nicolaus||Boost Price Target||Buy||$25.00 -> $26.00||N/A|
|5/5/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||$16.00||N/A|
|9/28/2015||Gabelli||Upgrade||Sell -> Hold||$13.50||N/A|
Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)Earnings History by Quarter for Lexicon Pharmaceuticals (NASDAQ LXRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017|| || || || || || || || |
|3/3/2017||Q4 2016||($0.51)||($0.31)||$15.56 million||$23.00 million||View||N/A|
|11/1/2016||Q316||($0.50)||($0.35)||$9.68 million||$27.70 million||View||N/A|
|8/4/2016||Q216||($0.40)||($0.37)||$12.36 million||$20.10 million||View||N/A|
|5/3/2016||Q1||($0.30)||($0.34)||$11.11 million||$12.50 million||View||N/A|
|3/1/2016||Q415||($0.38)||$0.76||$21.50 million||$127.30 million||View||N/A|
|11/6/2015||Q3||($0.36)||($0.34)||$0.44 million||$0.57 million||View||N/A|
|8/7/2015||Q215||($0.32)||($0.27)||$0.45 million||$376.00 million||View||N/A|
|4/29/2015||Q115||($0.04)||($0.04)||$1.10 million||$1.78 million||View||N/A|
|11/4/2014||Q3||($0.05)||($0.05)||$0.16 million||$0.40 million||View||N/A|
|8/7/2014||Q214||($0.05)||($0.05)||$0.13 million||$0.68 million||View||N/A|
|5/8/2014||Q114||($0.05)||($0.06)||$0.12 million||$277.00 million||View||N/A|
|2/28/2014||Q413||($0.06)||($0.03)||$1.66 million||$1.40 million||View||N/A|
|11/12/2013||Q3||($0.01)||($0.06)||$1.59 million||$0.24 million||View||Listen|
|2/21/2013||Q4 2012||($0.05)||($0.05)||$0.37 million||$0.22 million||View||N/A|
Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
2017 EPS Consensus Estimate: ($1.70)
2018 EPS Consensus Estimate: ($1.11)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Ownership Percentage: 5.77%Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/6/2016||James F Tessmer||VP||Sell||1,500||$15.00||$22,500.00|| |
|5/23/2016||James F Tessmer||VP||Sell||6,000||$13.00||$78,000.00|| |
|12/12/2014||C.V. Invus||Director||Buy||150,000||$0.88||$132,000.00|| |
|12/10/2014||C.V. Invus||Director||Buy||315,896||$0.90||$284,306.40|| |
|11/26/2014||International S.C.A. Artal||Director||Buy||149,253,731||$1.01||$150,746,268.31|| |
|10/23/2012||International S.C.A. Artal||Director||Buy||3,000,000||$2.25||$6,750,000.00|| |
Headline Trends for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
|Lexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - June 20 at 9:21 AM
|Lexicon Pharma (LXRX) Announces XERMELO In Combination With Somatostatin Analog Therapy As A ... - StreetInsider.com|
www.streetinsider.com - June 19 at 5:26 PM
|Lexicon Pharma (LXRX) Announces XERMELO In Combination With Somatostatin ...|
www.streetinsider.com - June 19 at 11:46 AM
|NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea|
finance.yahoo.com - June 19 at 11:46 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Raised to "Hold" at ValuEngine|
www.americanbankingnews.com - June 15 at 8:50 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Upgraded at BidaskClub|
www.americanbankingnews.com - June 14 at 7:20 PM
|Company News for June 12, 2017|
finance.yahoo.com - June 12 at 3:45 PM
|LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite - Nasdaq|
www.nasdaq.com - June 12 at 9:31 AM
|Today's Research Reports on Stocks to Watch: Lexicon Pharmaceuticals and Adamis Pharmaceuticals|
finance.yahoo.com - June 12 at 9:31 AM
|Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials|
finance.yahoo.com - June 12 at 9:31 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Short Interest Update|
www.americanbankingnews.com - June 11 at 12:46 PM
|Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017|
finance.yahoo.com - June 10 at 6:20 PM
|Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial - 24/7 Wall St.|
247wallst.com - June 10 at 8:58 AM
|Lexicon Pharma's (LXRX) Phase 3 inTandem3 Study For Sotagliflozin in Patients With Type 1 Diabetes Meets Primary Endpoint|
www.streetinsider.com - June 9 at 9:01 AM
|Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes|
finance.yahoo.com - June 9 at 9:00 AM
|Stock Traders Purchase High Volume of Call Options on Lexicon Pharmaceuticals (LXRX)|
www.americanbankingnews.com - June 9 at 7:08 AM
|$17.98 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter|
www.americanbankingnews.com - June 8 at 1:30 PM
|Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions - PR Newswire (press release)|
www.prnewswire.com - June 6 at 9:37 AM
|Zacks: Brokerages Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Earnings of -$0.44 Per Share|
www.americanbankingnews.com - June 6 at 7:16 AM
|Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions|
finance.yahoo.com - June 5 at 7:05 PM
|Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : June 5, 2017|
finance.yahoo.com - June 5 at 9:32 AM
|Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire (press release)|
www.prnewswire.com - May 31 at 6:47 PM
|Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences|
finance.yahoo.com - May 31 at 6:47 PM
|Oversold Conditions For Lexicon Pharmaceuticals (LXRX)|
www.nasdaq.com - May 30 at 6:07 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - May 26 at 9:25 AM
|Lexicon Pharmaceuticals (LXRX) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow|
seekingalpha.com - May 24 at 10:56 AM
|ETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 23, 2017|
finance.yahoo.com - May 23 at 5:57 PM
|Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : May 18, 2017|
finance.yahoo.com - May 18 at 8:45 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $17.98 Million|
www.americanbankingnews.com - May 12 at 1:52 PM
|Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In ... - PR Newswire (press release)|
www.prnewswire.com - May 11 at 6:53 PM
|Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes|
finance.yahoo.com - May 11 at 6:53 PM
|ETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 11, 2017|
finance.yahoo.com - May 11 at 6:53 PM
|Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) to Post -$0.44 Earnings Per Share|
www.americanbankingnews.com - May 10 at 4:26 PM
|Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017|
finance.yahoo.com - May 9 at 11:55 AM
|Gabelli Comments on Lexicon Pharmaceuticals, Inc.'s FY2017 Earnings (LXRX)|
www.americanbankingnews.com - May 8 at 9:48 AM
|HC Wainwright Reiterates $27.00 Price Target for Lexicon Pharmaceuticals, Inc. (LXRX)|
www.americanbankingnews.com - May 7 at 10:02 PM
|Gabelli Comments on Lexicon Pharmaceuticals, Inc.'s FY2019 Earnings (LXRX)|
www.americanbankingnews.com - May 5 at 7:58 PM
|Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference - PR Newswire (press release)|
www.prnewswire.com - May 5 at 7:48 AM
|Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference|
finance.yahoo.com - May 4 at 6:29 PM
|Edited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT|
finance.yahoo.com - May 4 at 11:48 AM
|Lexicon reports 1Q loss|
marketbeat.com - May 3 at 5:16 AM
|Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update|
finance.yahoo.com - May 2 at 7:42 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - May 1 at 12:28 PM
|Lexicon Pharmaceuticals To Host First Quarter 2017 Financial ... - Yahoo Finance|
finance.yahoo.com - April 29 at 12:20 AM
|Lexicon Pharmaceuticals (LXRX) Receiving Somewhat Positive Media Coverage, Analysis Shows|
www.americanbankingnews.com - April 28 at 8:20 PM
|Lexicon Pharmaceuticals To Host First Quarter 2017 Financial ... - PR Newswire (press release)|
www.prnewswire.com - April 28 at 7:19 PM
|Lexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017|
finance.yahoo.com - April 28 at 7:19 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $14.81 Million|
www.americanbankingnews.com - April 27 at 1:14 AM
|Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : April 26, 2017|
finance.yahoo.com - April 26 at 6:54 PM
|Lexicon Pharmaceuticals (LXRX) Receiving Somewhat Favorable Media Coverage, Analysis Shows|
www.americanbankingnews.com - April 25 at 9:24 PM
Lexicon Pharmaceuticals (LXRX) Chart for Thursday, June, 29, 2017